# CYCLERION THERAPEUTICS, INC. (KRSA) · Edgar & Edgarette company card

> Cyclerion Therapeutics (KRSA) grew revenue 3.7% in FY2025 to $2 million, operating margin -240% against a -3.8% median for pharmaceutical preparations, equity 91.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1755237 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KRSA) · [JSON](https://www.pops4.com/boards/company/KRSA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 3.7% |
| Revenue growth per year | -14.8% |
| Operating margin | -239.8% (prior year -181.4%) |
| Net margin | -170.1% |
| Operating cash flow | −$3M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $10M |
| Total equity | $9M |
| Equity ÷ assets | 91.0% |
| Return on equity | -38.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -78.78 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -239.8% in FY2025; revenue is hard to predict: its 80% range is ±53%

## Edgarette's reading

Exposure: revenue $2.1M (FY2025). Experience: revenue up 3.7% on the year, down 14.8% a year over 4 years; operating margin -239.8%, down from -181.4%. Soundness: equity 91.0% of assets, return on equity -38.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.7M and $5.4M next year (method v4.1: its own 1-year record of growth weighed at 0% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.5M to $5.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -239.8% against a -3.8% median; growth 3.7% against 13.7%.

Range logged 2026-09-24, receipt 1d02e09e74f4e44e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-09-11 ([filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526389318/0001193125-26-389318-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-15 · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526422893/0001193125-26-422893-index.htm)
- 8-K · filed 2026-09-11 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.05 Amendments to the Code of Ethics; 5.06 Change in Shell Company Status; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526389318/0001193125-26-389318-index.htm)
- 8-K · filed 2026-08-27 · 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/0001193125-26-369426-index.htm)
- 8-K · filed 2026-08-25 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526365150/0001193125-26-365150-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526332842/0001193125-26-332842-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/1755237/000119312526219478/0001193125-26-219478-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001755237.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1755237

## Cite

POPS4, Edgar & Edgarette: CYCLERION THERAPEUTICS, INC. (KRSA) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/KRSA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.